Zapping a neck nerve to rebuild Stroke-Damaged arms

NCT ID NCT07841431

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 25, 2026 · Last updated Sep 25, 2026

Summary

Researchers are testing whether an implanted vagus nerve stimulation device can help people regain arm and hand movement after an ischemic stroke. The trial enrolls adults in the subacute phase, three to six months after stroke, who have upper limb weakness. All participants receive the implant and are randomly assigned to active stimulation or a control setting, combined with upper limb rehabilitation. The main measure is change in arm and hand function after six weeks of hospital treatment.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
an implanted vagus nerve stimulation device delivering electrical pulses to the neck nerve
What this could lead to
If it works, vagus nerve stimulation could become a standard add-on to rehabilitation for people recovering arm and hand movement after a stroke.
What could go wrong
The trial is small and early, so results may not hold up in larger studies. Implanting a device carries surgical risks, and some participants may not improve.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 100 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Oct 2026

An estimate. Start dates often move.

Expected to finish

Dec 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 80 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. History of unilateral supratentorial ischemic stroke and in the subacute phase (3-6 months); 2. Age between 18-80 years, both male and female; 3. FMA-UE score of 20-50 (inclusive); 4. Ability to communicate, understand, and provide appropriate consent; participant can follow two-step commands; 5. Right or left upper limb weakness; 6. Active flexion/extension of the wrist or fingers; 7. Informed consent signed by the patient or a family member. Exclusion Criteria: 1. History of hemorrhagic stroke; 2. Persistent dysphagia or choking/coughing while eating or drinking; 3. Medications that, at study initiation, may significantly interfere with the effects of VNS on neurotransmitter systems; 4. Prior vagus nerve injury, bilateral or unilateral (e.g., injury during carotid endarterectomy); 5. Severe or more severe depression (Beck Depression Inventory \>29); 6. Candidates unsuitable for device implantation surgery (e.g., history of adverse reaction to anesthesia, deemed unsuitable as a surgical candidate by the surgeon, etc.); 7. Current use of any other stimulation device, such as a pacemaker or other neurostimulator; current use of any other investigational device or drug; 8. Preexisting neurological or psychiatric disorders before stroke onset that affect assessment of the condition; 9. Pregnancy, planned pregnancy, or breastfeeding during the study period; 10. Severe upper limb spasticity (modified Ashworth ≥3); 11. Severe sensory loss. Sensory loss will be measured using the upper extremity sensory portion of the Fugl-Meyer Assessment. The assessment involves light touch (two items) and proprioception (four items). The maximum score is 12; subjects with a score below 6 will be excluded from the study; 12. Other conditions that the investigator considers unsuitable for participation or that may pose a significant risk to the patient.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Ischemic stroke are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

More trials for these conditions

Other studies related to the condition(s) this trial covers.